Oryzon Genomics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Oryzon Genomics hat ein Gesamteigenkapital von $85.7M und eine Gesamtverschuldung von $21.3M, was einen Verschuldungsgrad von 24.8% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $114.2M bzw. $28.5M.

Wichtige Informationen

20.8%

Verhältnis von Schulden zu Eigenkapital

€17.99m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	€10.08m
Eigenkapital	€86.51m
Gesamtverbindlichkeiten	€24.16m
Gesamtvermögen	€110.67m

Jüngste Berichte zur Finanzlage

Recent updates

Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Jun 09

Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Apr 04

Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Jul 24

Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

May 01

Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

Feb 26

If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Jan 04

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ORYDie kurzfristigen Aktiva des Unternehmens (€13.9M) decken seine kurzfristigen Passiva (€14.6M) nicht.

Langfristige Verbindlichkeiten: ORYDie kurzfristigen Vermögenswerte des Unternehmens ($20.3M) übersteigen seine langfristigen Verbindlichkeiten ($11.7M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ORYDie Nettoverschuldung im Verhältnis zum Eigenkapital (7.7%) wird als zufriedenstellend angesehen.

Schulden abbauen: ORY Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 58% auf 24.8% zurückgegangen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ORY hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: ORY hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 8.7% pro Jahr abnimmt

Oryzon Genomics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

Recent updates

No longer forecast to breakeven

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

No longer forecast to breakeven

Oryzon Genomics, S.A. Announces Presentation of Final Data from Portico, Vafidemstat's Global Phase IIb Trial in Borderline Personal Disorder, at the 37th ECNP Annual Conference

Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024

Forecast breakeven date moved forward to 2025

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

Forecast breakeven date pushed back to 2026

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

New major risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Profitability

Forecast breakeven date pushed back to 2026

Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder

Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder

Forecast to breakeven in 2025

New major risk - Financial position

Forecast to breakeven in 2025

Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial

Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting

New minor risk - Share price stability

Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Insufficient new directors

Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease At the 2023 Peripheral Nerve Society Annual Meeting

Forecast to breakeven in 2025

Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Oryzon Genomics S.A. announced that it has received €1.800407 million in funding

Price target decreased to €8.83

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Consensus forecasts updated

Consensus forecasts updated

Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Oryzon Genomics S.A. announced that it expects to receive €20 million in funding from Nice & Green SA

Oryzon Genomics S.A. At Eha-2022: Iadademstat 42-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

Price target decreased to €9.00

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Price target increased to €12.00

Full year 2021 earnings: EPS misses analyst expectations

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

Oryzon Genomics S.A. Presents Iadademstat 36-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Announces $1 Million Grant from Kabuki Syndrome Philanthropists to Support A Precision Medicine Phase I/Ii Trial with Vafidemstat

First half 2021 earnings released: €0.019 loss per share (vs €0.026 loss in 1H 2020)

Oryzon Genomics S.A. Receives Approval to Start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

Oryzon Genomics, S.A. Announces FDA Approval of IND for Portico, Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML

ORYZON to Present New Clinical Data

Oryzon Genomics, S.A. Announces Successful pre-IND Meeting with FDA for the Clinical Development of vafidemstatin Borderline Personality Disorder

Oryzon Genomics S.A. Presents Vafidemstat 12-Month Clinical Data from Its Phase IIa Clinical Trials

Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

Earnings miss expectations

Full year 2020 earnings released

New 90-day high: €3.72

If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Oryzon Genomics S.A. Launches Pioneering Schizophrenia Precision Medicine Study in Collaboration with Columbia Psychiatry

New 90-day high: €3.21

New 90-day low: €2.70

Oryzon Genomics S.A. to Present Further Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology

Oryzon Genomics, S.A. Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. Announces Executive Changes

Third quarter earnings released

New 90-day low: €2.70

Oryzon Genomics S.A. has completed a Follow-on Equity Offering in the amount of €20.00075 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse